Order Article Reprints

Yang H, Zhou Y, Cheng X, Qiu C, Wang S, Xia Y, Huai X, Xiu Z, Wang J, He Y, et al. Safety, Tolerability, and Immunogenicity of a DNA Vaccine (pGX9501) Against SARS-CoV-2 in Healthy Volunteers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, and Dose-Ranging Phase I Trial. Vaccines. 2025; 13(6):573. https://doi.org/10.3390/vaccines13060573

Yang, Haijing, Yang Zhou, Xin Cheng, Chao Qiu, Shuo Wang, Yu Xia, Xuefen Huai, Zhenning Xiu, Jiarong Wang, Yue He, and et al. 2025. "Safety, Tolerability, and Immunogenicity of a DNA Vaccine (pGX9501) Against SARS-CoV-2 in Healthy Volunteers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, and Dose-Ranging Phase I Trial" Vaccines 13, no. 6: 573. https://doi.org/10.3390/vaccines13060573

Yang, H., Zhou, Y., Cheng, X., Qiu, C., Wang, S., Xia, Y., Huai, X., Xiu, Z., Wang, J., He, Y., Cao, G., Wei, Q., Wang, J., Ai, J., Zhang, H., Zhang, Y., Zhang, J., Zhang, W., & Wang, B. (2025). Safety, Tolerability, and Immunogenicity of a DNA Vaccine (pGX9501) Against SARS-CoV-2 in Healthy Volunteers: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, and Dose-Ranging Phase I Trial. Vaccines, 13(6), 573. https://doi.org/10.3390/vaccines13060573